CL2021002013A1 - Biomarcadores para el diagnóstico de cáncer de ovario - Google Patents

Biomarcadores para el diagnóstico de cáncer de ovario

Info

Publication number
CL2021002013A1
CL2021002013A1 CL2021002013A CL2021002013A CL2021002013A1 CL 2021002013 A1 CL2021002013 A1 CL 2021002013A1 CL 2021002013 A CL2021002013 A CL 2021002013A CL 2021002013 A CL2021002013 A CL 2021002013A CL 2021002013 A1 CL2021002013 A1 CL 2021002013A1
Authority
CL
Chile
Prior art keywords
biomarkers
glycopeptide
diagnosis
methods
ovarian cancer
Prior art date
Application number
CL2021002013A
Other languages
English (en)
Inventor
Gege Xu
Lieza Marie Araullo Danan-Leon
Daniel Serie
Original Assignee
Venn Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venn Biosciences Corp filed Critical Venn Biosciences Corp
Publication of CL2021002013A1 publication Critical patent/CL2021002013A1/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes
    • H01J49/34—Dynamic spectrometers
    • H01J49/40—Time-of-flight spectrometers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Organic Chemistry (AREA)
  • Mathematical Physics (AREA)
  • Bioethics (AREA)

Abstract

En la presente se establecen biomarcadores de glicopéptidos útiles para el diagnóstico de enfermedades y afecciones, tales como, de modo no taxativo, el cáncer (por ejemplo, de ovario), una enfermedad autoinmunitaria, fibrosis y afecciones por envejecimiento. También se establecen en la presente métodos de generación de biomarcadores de glicopéptidos y métodos de análisis de glicopéptidos mediante espectroscopía un péptido o glicopéptido que consiste a de masas. También se establecen en la presente métodos de análisis de glicopéptidos mediante algoritmos de aprendizaje automático.
CL2021002013A 2019-02-01 2021-07-30 Biomarcadores para el diagnóstico de cáncer de ovario CL2021002013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962800323P 2019-02-01 2019-02-01

Publications (1)

Publication Number Publication Date
CL2021002013A1 true CL2021002013A1 (es) 2022-01-21

Family

ID=69771064

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002013A CL2021002013A1 (es) 2019-02-01 2021-07-30 Biomarcadores para el diagnóstico de cáncer de ovario

Country Status (12)

Country Link
US (1) US20220139499A1 (es)
EP (1) EP3918334A1 (es)
JP (1) JP7493815B2 (es)
KR (1) KR20210124269A (es)
CN (1) CN113439213A (es)
AU (1) AU2020216996A1 (es)
BR (1) BR112021014978A2 (es)
CA (1) CA3128367A1 (es)
CL (1) CL2021002013A1 (es)
IL (1) IL285218A (es)
SG (1) SG11202108327VA (es)
WO (1) WO2020160515A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11592448B2 (en) * 2017-06-14 2023-02-28 Discerndx, Inc. Tandem identification engine
EP3676393A4 (en) 2017-09-01 2021-10-13 Venn Biosciences Corporation IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT
KR20210145210A (ko) 2019-03-29 2021-12-01 벤 바이오사이언시스 코포레이션 질량 분석 데이터의 경계 자동 검출
JP7380515B2 (ja) * 2020-10-19 2023-11-15 株式会社島津製作所 質量分析を用いた試料分析方法及び試料分析システム
EP4305427A1 (en) * 2021-03-08 2024-01-17 Venn Biosciences Corporation Biomarkers for determining an immuno-oncology response
AU2022276734A1 (en) * 2021-05-18 2024-01-04 Venn Biosciences Corporation Biomarkers for diagnosing ovarian cancer
KR20240083172A (ko) * 2021-08-04 2024-06-11 벤 바이오사이언시스 코포레이션 대장암 또는 진행성 선종 진단을 위한 바이오마커
WO2023019093A2 (en) * 2021-08-07 2023-02-16 Venn Biosciences Corporation Detection of peptide structures for diagnosing and treating sepsis and covid
CA3239488A1 (en) * 2021-11-30 2023-06-08 Daniel SERIE Diagnosis of pancreatic cancer using targeted quantification of site-specific protein glycosylation
WO2024059750A2 (en) * 2022-09-16 2024-03-21 Venn Biosciences Corporation Diagnosis of ovarian cancer using targeted quantification of site-specific protein glycosylation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776550B2 (en) 2005-05-05 2010-08-17 Philadelphia Health & Education Corporation Diagnosis of liver pathology through assessment of protein glycosylation
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
WO2009138392A1 (en) 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
JP2012517607A (ja) 2009-02-20 2012-08-02 オンコノム，インコーポレイテッド 大腸癌の診断及び予後判定のための用具セット及び方法
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
EP3676393A4 (en) 2017-09-01 2021-10-13 Venn Biosciences Corporation IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT
CN111479934A (zh) 2017-10-18 2020-07-31 韦恩生物科技股份公司 用于诊断和治疗监测的生物学指标的鉴定和用途

Also Published As

Publication number Publication date
JP2022524298A (ja) 2022-05-02
CN113439213A (zh) 2021-09-24
IL285218A (en) 2021-09-30
CA3128367A1 (en) 2020-08-06
SG11202108327VA (en) 2021-08-30
WO2020160515A1 (en) 2020-08-06
AU2020216996A1 (en) 2021-09-16
KR20210124269A (ko) 2021-10-14
US20220139499A1 (en) 2022-05-05
BR112021014978A2 (pt) 2022-01-04
EP3918334A1 (en) 2021-12-08
JP7493815B2 (ja) 2024-06-03

Similar Documents

Publication Publication Date Title
CL2021002013A1 (es) Biomarcadores para el diagnóstico de cáncer de ovario
MY202410A (en) Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
WO2016109813A3 (en) Human pluripotent stem cell-based models for predictive developmental neural toxicity
BR112017018821A2 (pt) métodos para quantificação de níveis de insulina através de espectrometria de massa
WO2018072862A8 (de) Verfahren zum auswerten von daten einer massenspektrometrie und massenspektrometrisches verfahren sowie ein maldi tof massenspektrometer
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112018015965A2 (pt) método para determinação de helicobacter pylori
WO2017038702A8 (ja) 蛍光ｘ線分析装置
EP3584166A3 (en) Translucent illuminated evacuation slide
MX2019002929A (es) Biomarcadores de arn para angioedema hereditario.
CY1125303T1 (el) Meθοδοι γia thn aπολyth πoσotikoπoihσh πολυπεπτιδιων xamhλης aφθονιας me th xphσh φασματομετριας mazaς
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
EP3756014A4 (en) TISSUE ANALYSIS BY MASS SPECTROMETRY
CO2022001531A2 (es) Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc
EP3759469A4 (en) CHAIN TEST DEVELOPMENT DIAGNOSIS ANALYSIS
EP4088219A4 (en) MOTION CORRESPONDENCE ANALYSIS
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
CL2022002000A1 (es) Biomarcadores para el diagnóstico del cáncer de ovario
WO2022246416A3 (en) Biomarkers for diagnosing ovarian cancer
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso